To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:
- • State issued document with your organization's Federal Tax ID Number
- • State issued document with your organization's Resale Tax ID Number
- • City or County issued Business License
- • State Department of Health Services License
- • Any other ID issued by the State that includes the business name & address
* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. Avantor will not lift restrictions for residential shipping addresses.
- Description:Hydroxypyridinium Crosslinks HPLC Assay (100 Tests)
- Size:1 kit
- Environmentally Preferable:
- Cat. No.:102994-128
- Supplier no.:CSL34-H100
The Hydroxypyridinium Crosslinks HPLC Assay is used to detect hydroxypyridinium crosslinks in urine
- Incubation Time: 4 hours 20 minutes
- Sample Size: 1 mL
- Sample Type: Urine
Pyridinium and deoxypyridinium are built as intramolecular crosslinkers during the maturation of collagen. During bone resorption collagen is degraded and the pyridinium-crosslinks are excreted. They are not reutilized by the body and excreted in the urine. The crosslinks are not released during the de novo synthesis of collagen. They are specific for resorptive processes. Neither PYD nor DPD are taken up by nutrition. Therefore the determination of the crosslinks is independent from the diet. PYD is found in cartilage, ligaments and bone, whereas DPD is rather specific for bone. The crosslink excretion shows a strong circadian rhythm with a maximum in the early morning hours. Reliable data can be obtained with a 24h or a creatinine corrected morning urine. An elevated crosslink excretion is shown in osteoporotic women. Crosslink levels decrease during treatment with estrogen (Seibel et al. 1994). Therefore they are suited for therapy monitoring (Ganero et al. 1994). The measurement of pyridinium crosslinks is an independent predictor for future bone fractures (Ganero et al. 1995). Increased crosslink concentrations are also described in patients with Paget’s Disease, primary hyperparathyroidism and bone metastasis.